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The genus Streptomyces represents one of the largest producers of molecules with antibiotic 
activity. The whole genome sequencing of the endophytic microorganism Streptomyces sp. 
CBMAI 2042 revealed 35 gene clusters encoding for secondary metabolism including 3 non-
ribosomal peptide synthetases (NRPS) and 7 NRPS-hybrids. Combining genome mining and 
cultivation profile analysis, the depsipeptide ionophore valinomycin was identified as one of the 
main metabolites produced by this strain. To better understand the metabolic machinery codified 
in CBMAI 2042 genome an adenylation domain from a hybrid NRPS cluster was deleted through 
a double crossing knockout experiment. Though the deletion was not plentiful to elucidate the 
encoded NRP metabolite related to the adenilation domain, an astounding increase of 10.5-fold 
in valinomycin production was observed in the mutant. These results suggest a metabolic flux 
redistribution of common substrates as an outcome of a gene target deletion.
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Introduction
The genus Streptomyces is a highly prolific producer 
of structural diverse natural products. These actinobacteria 
represent an outstanding source for leads that inspire and 
guide the drug discovery programs.1,2 Among the diversity 
of biosynthesized metabolites, non-ribosomal peptides 
(NRPs) have a wide spectrum of biological activity 
including antibiotic (vancomycin),3 immunosuppressant 
(cyclosporine A) and antineoplasics (enniatins).4 Typically, 
complex peptides in bacteria are produced by non-ribosomal 
peptides synthetases (NRPS), a remarkable assembly-line 
multienzyme system able to extend and modify amino acid 
chain, in specific enzyme locus termed modules.5 Many 
NRPS follow the canonical assembly line as described, but 
variations including different constructions of the modules, 
iterative mechanisms, as well as the incorporation of more 
unusual extender units are observed.
Despite the wide applicability, NRP discovery and 
exploitation are limited, as manageable amounts are 
necessary for subsequent biological and pharmacological 
studies. Reciprocally most of them are impractical to be 
obtained by chemical synthesis due to the complexity 
of their backbones. The possibility to interfere in 
biosynthetic pathways in a genetic level expanded the 
number of strategies available to study the megasynthetases 
enzymology responsible to outturn non-ribosomal 
peptides6,7 enabling to improve efficiency of production 
and to increase fermentation titers. Correspondingly, the 
enhancement of natural hosts capable to overexpress a 
specific pathway is an attractive approach when a significant 
amount of purified material is needed to advance in clinical 
trials, for instance.8 In addition, tools for gene deletions,9,10 
gene replacements, heterologous expression in appropriated 
hosts and insertion of stronger promoters11,12 are among 
the most suitable methodologies of choice for genetic 
manipulation of the biosynthetic pathways.
Streptomyces sp. CBMAI 2042 is an endophytic 
isolated from Citrus sinensis branches. The whole 
genome sequencing of this actinobacteria evidenced a 
high biosynthetic potential uncovering third five gene 
clusters related to secondary metabolism. It was possible 
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to identify suitable classes of enzyme assembly lines 
encrypted to produce polyketides (PKs) and NRPs. During 
our dereplication approach, valinomycin (Figure 1) was 
identified as one of the main metabolite produced by 
fermentation of this strain. 
Valinomycin (VLM) is a depsipeptide ionophore 
that plays several biological functions such as 
antibacterial, antiviral and anticancer. It is also a powerful 
therapeutic for the treatment of severe acute respiratory 
syndrome (SARS).13 Its production was already described 
in several Streptomyces strains around the world14 and its 
biosynthetic gene cluster was well-defined throughout S. 
levoris A915 and S. tsusimaensis ATCC 1514113 studies. Two 
large NRPS genes vlm1 and vlm2 and other small functional 
(ORFs) are involved in valinomycin biosynthesis. VLM1 
and VLM2 are responsible for incorporation of D-hydroxy-
isovaleric acid, D-valine, L-lactic acid and L-valine. A 
thioesterase domain located in VLM2 promotes final 
cleavage and cyclization.
In 2014, Neubauer and co-workers16 were able to clone 
and co-express VLM1 and VLM2 from S. tsusimaensis in 
an engineered E. coli strain (BJJ01) and reconstitute the 
biosynthesis of valinomycin in heterologous host. After 
optimizing a fed-batch culture VLM production17 was 
increased 33-fold (10 mg L-1) whereas the co-expression 
of a type II thioesterase (TEII)18,19 allowed a 43-fold 
increase (13 mg L-1), both compared to the initial batch 
culture (0.3 mg L-1). This system was later used on 
fed-batch cultivation to develop a modeled scaled-up 
bioprocess for the antibiotic assembly. Lee et al.20 also 
succeed to improve four-fold the VLM production in 
Streptomyces sp. M10 by redirecting the flux of a common 
precursor in bafilomycin and valinomycin biosynthesis by 
gene deletion experiments.
In this study we describe a 10.5-fold increase in 
valinomycin production by Streptomyces sp. CBMAI 
2042 as a result of a target gene deletion. The deleted 
gene holds an adenylation domain of a hybrid NRPS-PKS 
(NRPS-polyketide synthase) cluster encoding to an 
unknown metabolite annotated from the whole genome 
sequencing and, apparently, unrelated to valinomycin gene 
cluster. Our experiments suggest a deep modification in 
the functional metabolism of CBMAI 2042 after punctual 
deletion, involving a redistribution of common precursors.
Experimental
Bacterial strain and culture conditions
Streptomyces sp. CBMAI 2042 was grown in TSBY 
liquid medium (3% tryptone soy broth, 10.3% sucrose, 
0.5% yeast extract) at 30 °C and 250 rpm for preservation 
and genomic deoxyribonucleic acid (DNA) extraction. For 
valinomycin production, the seed medium was TSBY liquid 
medium and the expression liquid medium was GYM (1% 
malt extract, 0.4% yeast extract, 0.4% dextrose) or A liquid 
medium (0.4% peptone, 0.2% yeast extract, 0.4% meat 
extract, 0.2% soy-bean meal, 2.0% maltose and 1.0% potato 
dextrin). Fermentation was carried out after inoculating 
10% of 2-day old seed culture in a 500 mL Erlenmeyer fitted 
with a metal spring containing 100 mL of GYM media, at 
30 °C and 180 rpm for 7 days.
DNA manipulation
Chemicals were purchased from Sigma-Aldrich®, 
restriction endonuclease (NdeI) was purchased from Thermo 
Scientific®. Plasmid DNA was isolated from an overnight 
culture using Mini Prep kit (QIAGEN®) following the 
manufacturer’s protocol. Polymerase chain reaction (PCR) 
amplification for plasmid construction was carried out using 
Phusion Flash High-Fidelity master mix from Thermo 
Scientific®. My RedTaq polymerase (Bioline®) was used 
for screening purposes. Genomic DNA was isolated using 
a protocol described and adapted from Sharma and Singh.21
Plasmid construction
The DNA fragments flanking the adenylation domain 
were amplified from Streptomyces sp. CBMAI 2042 
genomic DNA by PCR using oligonucleotides pΔcal-F1 
(5’-TGATCAAGGCGAATACTTCATATGCGCGTGGG 
C G AG C G AG C G C AG C T C - 3 ’ )  a n d  p Δ c a l - R 1 
(5’-GGCCCGGTGTTGCGGGAGCCCTTCGCC 
GGTGCTCCG-3’) to construct fragment 1 and pΔcal-F2 
Figure 1. Chemical structure of valinomycin. 
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(5’-GCCGATCACCGCCGGAGCACCGGCGAAGGG 
CTCCCG-3’) and pΔcal-R2 (5’-CCGCGCGGTCG 
ATCCCCGCATATGATGGACGGGTACGAGGAGG 
ATGTC-3’) to construct fragment 2. For DNA assembly 
1 µL of pYH7 vector previously digested with NdeI and 
3 µL of each fragment were added in 13 µL of Gibson 
DNA assembly mix.22 The reaction was carried out during 
1 h at 50 °C, then 10 µL of the mix were used to transform 
chemically competent cells of E. coli DH10B. Around 
30 recombinants were observed in lysogeny broth (LB)-
agar plate supplemented with apramycin (25 µg mL-1). 
At least 5 colonies were selected to extract plasmid and a 
double restriction assay using NdeI and EcoRI was used 
in a restriction analysis to confirm the correct construction 
of pBSΔcal (Figure S2, Supplementary Information (SI) 
section).
Intergeneric conjugation
The resulting plasmid pBSΔcal was introduced in 
electrocompetent cells of E. coli ET12567/pUZ8002. The 
intergeneric conjugation with Streptomyces sp. CBMAI 
2042 was performed based on methods described in the 
literature.23 For selection of first crossover’s exconjugants, 
apramycin and nalidixic acid were used at concentrations 
of 25 µg mL-1. Exconjugants were grown in SFM-agar 
(2% soya flour, 2% D-mannitol, 2% bacteriological agar) 
at 30 °C without antibiotics during 16 h. Afterwards, 
the SFM plates were overlaid with a solution containing 
apramycin (25 µg mL-1) and nalidixic acid (50 µL mL-1) and 
left for 48 hours at 30 ºC. Colonies presenting apramycin 
resistance (potential mutants) were transferred to another 
SFM-agar plate without antibiotics (96 h, 30 ºC), to allow 
the second crossover event. To check the loss of apramycin 
resistance, potential mutants were transferred to SFM-
agar plates supplemented with apramycin (25 µg mL-1) 
and nalidixic acid (25 µg mL-1). Colonies that did not 
appear in apramycin-SFM plates were cultivated in TSBY 
liquid medium and the genomic DNA was extracted 
for PCR analysis. Purified genomic DNA was used as 
a template with oligonucleotide pair scree_pΔcal_F 
(5’-CAGGAGCCACAGGAAACGCGGCAG-3’) and 
scree_pΔcal_R (5’-CTGACCGTCACGCTGCGCGAA 
CTCC-3’). Detailed PCR characterization of the deleted 
mutant can be accessed on SI section (Figures S4 and S5).
LC-MS/MS analysis of metabolites
Liquid chromatography tandem-mass spectrometry 
(LC-MS/MS) analysis was performed using an ultra-
performance liquid chromatography (UPLC, Agilent 
technologies 1200 series) coupled to a hybrid quadropole-
time of flight Agilent Q-TOF mass spectrometer fitted 
with an electron spray ionization (ESI) source. The 
source condition gas was: gas temperature 290 °C, drying 
gas flow rate at 14 L min-1; sheath gas temp of 300 °C; 
Vcap 300 V; Fragmentor at 150 V; Octa 750 V. The mass 
spectrometer worked in positive ion mode scanning mass 
from m/z 200 to 1500. The UPLC column used in this work 
was Extend C-18 1.8 µM (2.14 × 50 mm, Agilent) and the 
solvent gradient system of acetonitrile (solvent B) and 
water (solvent A) both containing 0.1% formic acid (v/v) 
was used. For quantification experiments the samples were 
eluted with a flow rate of 0.7 mL min-1 and the following 
linear gradient: 80% B; 0-3 min, 80% B to 90% B; 3-5 min, 
90% B to 99.9% B, 5-7 min hold at 99.9%. For metabolic 
profile the linear gradient was: 5% B; 0-3 min, hold 5% 
B; 3-20 min 5% B to 70% B, 20-25 min 70% B to 99% B 
then 25-30 hold 99% B. All gradients finished with 3 min 
of equilibration time at initial gradient. 
Results and Discussion
The Streptomycetes are among the most reliable 
sources of secondary metabolites bearing wide spectrum 
of biological activity. The biosynthetic potential of these 
genera was reinforced after more than 1500 Streptomyces 
whole genome sequences have been deposited in Genomes 
On Line Database (GOLD). It has been verified that 
symbiotic microorganisms as endophytic have been 
coevoluting with the plant host during many years and 
represent a generous source for new natural products with 
relevant pharmacological activity.1
Streptomyces sp. CBMAI 2042 is a Citrus sinensis 
endophyte and was identified based on its 16S rDNA 
gene sequence. The interest in this strain relies in our 
previous observation on the ability to inhibit the growth 
of Bacillus megaterium, Staphylococcus aureus and 
Candida albicans24 by diffusion test in agar plates. To 
better know its potential, this actinomycete was completely 
sequenced using ilumina technology (MiSeq) providing a 
linear chromosome with ca. 8 Mbp, which were divided 
in 4 contigs. Analysis through antiSMASH25 platform 
highlighted 35 biosynthetic gene clusters (BGC) related 
to the secondary metabolism (Table S1, SI section). The 
presence of NRPS and PKS could be accented as previously 
implied.24
Based on the whole genome sequence information, 
Streptomyces sp. CBMAI 2042 was cultivated under 
several different nutritional conditions, however, A and 
GYM medium were elected for further fermentation 
experiments due to the most diverse profile of secondary 
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metabolites disclosed. Through LC-MS/MS analysis and 
dereplication valinomycin was identified as one of the 
main metabolites produced under culture cultivation. 
Using ESI(+) as ionization technique, valinomycin was 
detected as its protonated (m/z [M + H]+ 1111.6399, 
calcd. 1111.6390, 0.8 ppm error), ammoniated (m/z 
[M + NH4]+ 1128.6693, calcd. 1128.6685, 3.4 ppm 
error), sodiated (m/z [M + Na]+ 1133.6272, calcd. 
1133.6209, 5.5 ppm error), and potassiated molecules 
(m/z [M + K]+ 1149.5927, calcd .1149.5949, 2.3 ppm error) 
(Figure S1, SI section). High accuracy MS/MS data 
acquired in a QTOF mass spectrometer of the most 
abundant ion (m/z 1128.6693) undoubtedly confirmed 
the production of the cyclic depsipeptide antibiotic via 
the structurally diagnostic fragment ions resulting from 
losses of CO (m/z 1083.6451), Hiv-Val (m/z 884.5229), 
Lac-Val (m/z 713.4339), Hiv-Val (m/z 514.3104), Lac-Val 
(m/z 343.2215) and Hiv-Val (m/z 144.1035) (Table S2, SI 
section). The retention time (tR 22.13 min) and MS data 
of standard VLM (Sigma-Aldrich®) also corroborate to 
undoubtedly identify the metabolite.
Depsipeptides scaffolds are typically biosynthesized by 
non-ribosomal peptide synthetases (NRPS). The genome 
of Streptomyces sp. CBMAI 2042 contains three NRPS 
related genes and five hybrid clusters codifying PKS-NRPS 
scaffolds. Among the gene clusters spotted in Table S1, SI 
section, only the BGC 30 shares important homology with 
the genes responsible to valinomycin biosynthesis. This 
BGC was fully analyzed and correlated with those reported 
for valinomycin production in Streptomyces tsusimaensis13 
and S. levoris.15 antiSMASH output of the whole genome 
sequencing revealed two contiguous open reading frames, 
spanning 10341 bp to vlm1 and 8031 bp to vlm2, both 
correlated with valinomycin biosynthesis. These ORFs 
encode two non-ribosomal peptide synthetase with very 
significant sequence identity to vlm1 (84%) and vlm2 (85%) 
from S. tsusimaensis.13 Linked to vlm1 there is a type II 
thioesterase believed to act as a proofreader during the release 
of misprimed thioesters from carriers proteins.26 Transport 
related genes and other genes with no putative function on 
valinomycin biosynthesis were also observed (Figure 2).
By mining genome sequencing, the BGC 34 was 
predicted as a thiopeptide-NRPS-t1-PKS sharing 33% 
correspondence to a lactazole27 framework. This BGC 
contains essential genes correlating to a thiopeptide 
natural product as a class I lantibiotic dehydratase from 
Streptomyces lactacystinaeus (48% lazB), a known 
lactazoles producer. Genes encoding for the enzymes 
homologs dehydrogenase (53% lazF), cyclodehydratase 
(64% lazE), hypotetical protein (42% lazD) and an own 
putative peptide leader (citA) were also predicted. An 
homolog for lazC was not observed. A lipopetide structure 
related NRPS-t1-PKS was annotated on the left arm of the 
gene cluster (Figure 3).
With the intention to promote a metabolic profile 
differentiation a gene knockout was planned to generate a 
Figure 2. Homologues valinomycin biosynthetic gene clusters. (a) BGC from Streptomyces tsusimaensis ATCC 15141 (adapted from reference 13); 
(b) BGC from Streptomyces sp. CBMAI 2042 annotation. In black are the biosynthetic genes (23-vlm1; 24-vlm2), striped are transport-related genes and 
in grey are other/non-biosynthetic genes.
Figure 3. Comparison between (a) cluster 34 and (b) lactazole biosynthetic gene cluster from Streptomyces lactacystinaeus.
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NRPS- mutant via double crossing over experiments. The 
elected gene encodes an NRPS-t1-PKS annotated in cluster 
34. The expectation when designing this experiment was 
to get any insight about this gene cluster functionality as 
NRP producer or as a post-translational modifier during the 
thiopeptide biosynthesis. Remarkably, the main difference 
observed by comparison of the wild type and cal- mutant 
metabolic profile was the intensity of some peaks with a 
considerably enhancement in valinomycin production.
Exploring the outline that most gene clusters are 
substrate regulated, experiments involving knockouts of 
unique modules and domains responsible for recognition 
and modification of common building blocks could 
be a viable strategy to increase production of a target 
metabolite.20 Meng et al.28 succeeded to improve 24% 
the avermectin production in Streptomyces avermitilis by 
knocking out the gene rpp from a type III PKS specific 
to recruit malonyl-CoA subunits. The competing type I 
PKS responsible to biosynthesize the reduced polyketide 
uses this same precursor as building block. As cited 
before, Lee et al.20 promoted the disruption of bafV gene 
responsible to provide isobutyric acid to the biosynthesis of 
bafilomycin in Streptomyces sp. M10. A null bafV mutant 
increased 1.5-fold the valinomycin production due to the 
redistribution of the common building block ketoisovaleric 
acid.
Neubauer’s VLM synthetases studies identified L-Val 
as precursor for both the L- and D-form of valine in 
valinomycin. A deamination reaction to the corresponding 
keto acids and subsequent reduction produces the hydroxy 
acid precursors constituents, D-α-hydroxyisovaleric acid 
(D-Hiv) and L-lactate (L-Lac) from the α-amino acids. 
These results also demonstrate that VLM1 and VLM2 are 
highly specific for α-ketoisovaleric acid (Kiv) and pyruvate 
(Pyr) incorporation.16
The NRPS-t1-PKS gene is predicted to compose three 
units of condensation domain, one of them specific to insert 
subunits from the pyruvate pathway in the construction 
of lipopeptides also called cal domain.29 Consulting the 
MIBiG repository prediction we have found homology 
to an NRPS gene associated to cystomanamides (CtmA) 
lipopeptides (37%) from Cystobacter fuscus Mcy911830 
and a thiazoline related compound, micacocidin (MicC), 
from the bacterium Ralstonia solanacearum (31%).31 
The similarity among these primary sequences within 
valinomycin main proteins were compared using multiple 
sequence alignment (Muscle)32 (Figure 4). All incorporated 
subunits encoded by those sequences rely on pyruvate 
pathway essential to afford precursors involved in 
valinomycin biosynthesis.
Based on these results we proceed to perform 
valinomycin quantification in the mutant (NRPS-) and 
wild type. Both strains were grown during 2 days in TSBY 
liquid medium at 30 °C and 250 rpm, after that an aliquot 
of 1 mL of each flask were transferred to GYM and A liquid 
medium which were maintained for 7 days. Cells were 
harvested by centrifugation at 4000 rpm, during 10 min at 
25 °C. Aliquots (100 mL) of supernatant were extracted 
with same volume (1:1) of ethyl acetate and evaporated, 
then dissolved in 1 mL of acetonitrile/water. From those 
stock solutions, samples were prepared in triplicate 
by 100 times dilution and quantified in LC-MS/MS 
(Q-TOF 6500 iFunnel series). 
The calibration curve linearity was evaluated in a range 
of 0.05-4.00 µg mL-1 of VLM standard solution purchased 
from Sigma-Aldrich. The curve showed a linear regression 
coefficient of 0.99 (Figure S3, SI section). Quantification of 
VLM was done by 103 dilution extracts analysis followed 
by linear regression equation interpolation (Table S1, SI 
section). The wild type Streptomyces sp. CBMAI 2042 
Figure 4. Comparison among the conserved adenylation domain motifs responsible to biosynthesize valinomycin (VLM1 and VLM2), cystomanamides 
(CtmA), micacocidin (MicC) and the investigated NRPS-34 gene (NRPS-34).
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produces near to 0.231 ± 0.087 mg L-1, whereas cal- mutant 
yields near to 1.290 ± 0.538 mg L-1 representing an 
increasing titer about 5.58-fold. Changing to A liquid 
medium we could obtain 0.491 ± 0.221 mg L-1 for the wild 
type, whereas mutant produces 5.171 ± 1.048 mg L-1, an 
increased production of 10.5-fold. 
Quantification experiments demonstrated an increased 
production of valinomycin titers by 10.5-fold in A liquid 
medium and 5.58-fold in GYM liquid medium. For each 
1000 mL of GYM liquid medium analyzed we could expect 
1.29 mg of valinomycin in cal- mutant, whereas in the 
wild type we could observe only 0.23 mg of valinomycin 
(Tables S3 and S4, SI section). The most productive medium 
liquid A resulted in 5.17 mg of valinomycin in cal- mutant, 
while 0.49 mg was quantified in the wild type (Figure 5). 
Apparently, A liquid medium is richer in nutrients compared 
to the GYM (DNA manipulation subsection), favoring 
incremental production of the depsipeptide. 
Conclusions
Genome sequencing of the endophytic Streptomyces sp. 
CBMAI 2042 identified at least 35 gene clusters encoding 
to secondary metabolism. Dereplication methodologies 
revealed that Streptomyces sp. CBMAI 2042 is a promising 
producer of cyclodepsipeptides scaffolds. Analyzing 
those extracts it was possible to identify the production 
of valinomycin. 
To get a better understanding about the metabolic 
functionality of adenylation domain involved in biosynthesis 
of a hybrid NRPS gene cluster, a knockout experiment was 
performed and resulted in overexpression of valinomycin 
titers about 5.58-fold in GYM medium, whereas in A 
medium the increment was about 10.5-fold. Those sets of 
results revealed a deep modification in substrate efflux that 
can be a powerful tool to increase titers of related secondary 
metabolites in Streptomyces species. 
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a PDF file.
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